Robert Duggan
Robert Duggan is number 15 in the 311 Private Wealth Index, with disclosed holdings in listed companies worth about $12.3bn, mainly in Summit Therapeutics. That is about 63,846 times the wealth of a typical US household. 311 Origin: executive. 311 Giving Score: 2 out of 5 (provisional). 311 Future Exposure: high (58/100), driven by technology change in healthcare (76/100), led by 5G, Artificial Narrow Intelligence, Biometric Sensors; 82% of disclosed wealth in one company.
Part of the 311 Private Wealth Index (311institute.com). Last updated .
Disclosed holdings
| Company | Value | Latest filing | Shares |
|---|---|---|---|
| Summit Therapeutics | $10.1bn | Proxy statement, 17 April 2026 | 570,073,879 at $17.68 |
| Pulse Biosciences, Inc. | $2.2bn | Proxy statement, 11 May 2026 | 48,789,438 at $45.59 (closing price, 15 October 2026) |
Source of the holding: Summit Therapeutics 2026 proxy statement; Pulse Biosciences 2026 proxy statement.
311 Future Exposure: High
Score 58 out of 100: technology 76/100 and trends 40/100. What drives it:
- Technology change in healthcare (76/100), led by 5G, Artificial Narrow Intelligence, Biometric Sensors
- 82% of disclosed wealth in one company
Technology exposure uses the 311 Starburst: how strongly each emerging technology affects this industry, weighted by how soon it reaches widespread use. Trend exposure covers tariffs and export controls, international sanctions, concentration of wealth. Evidence on company-specific trends is being added. Explore the Starburst.
Giving
Robert Duggan is an officer or trustee of Robert W Duggan Foundation and Trish Joy Foundation. In their latest tax filings (Form 990-PF, 2022) they reported grants of $1.3m and assets worth $112m, together 0.92% of the disclosed wealth above. 311 Giving Score: 2 out of 5 (provisional).
How this figure is calculated
Shares reported in SEC insider filings (Forms 3, 4 and 5), at the latest holding each filing reports, valued at the latest price disclosed in those filings, or at the latest closing price where no recent trade price was filed. Share classes that convert one for one into listed shares are counted at the listed price. Holdings that the filings say belong to investment funds managed by the person, and unvested performance awards, are left out; shares reported jointly by several family members are counted once; where insider filings count the same shares more than once, the figure is capped at the holding in the company's latest proxy statement. Where a holding is not covered by US insider filings, the latest annual report (Form 20-F), proxy statement or ownership filing (Schedule 13D) is used instead, as linked in the table. Private companies, cash, property and holdings listed outside the United States are not included, so this is a minimum, not total wealth. The household comparison uses $192,700, the median US household wealth in the Federal Reserve Survey of Consumer Finances (2022, the latest published).
Related
- Innovation profile of Miami
- United States: economy and key statistics
- The 311 Private Wealth Index
- The 311 Titans Index
- All 311 Indexes
Others in the index with Summit Therapeutics as their main holding
- Maky Zanganeh (#180)
- Yu Xia (#202)
Questions and answers
What is Robert Duggan's net worth?
Robert Duggan has disclosed holdings in listed companies worth about $12.3bn, according to the 311 Private Wealth Index. This is a minimum: private companies, cash and property are not included.
How much are Robert Duggan's disclosed holdings worth?
About $12.3bn in listed companies, ranking Robert Duggan number 15 in the 311 Private Wealth Index.
Where does Robert Duggan's wealth come from?
Mainly from holdings in Summit Therapeutics.
Sources: SEC insider filings, proxy statement.
© 311 Institute 2026. Facts from official filings and the sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.